Oxford Nanopore: Everything you need to know about Oxford Nanopore
Oliver Brett October 1, 2021 5:00 PM
Oxford Nanopore, whose DNA sequencing technology has been essential in tracking Covid-19 variants around the world, completed a highly successful IPO on September 30, 2021. Read on to find out how a company started by three Oxford University scientists in 2005 has become a key player in global biotech.
How much is Oxford Nanopore worth?
Oxford Nanopore made an extremely impressive market debut in London.
A rise in its share price of as much as 44% after the first day of shares exchanging hands left the firm valued at £4.9bn, in London’s biggest biotech listing since the allergy specialist Circassia floated in 2014.
Nanopore shares had been priced at 425p in the IPO, towards the upper end of its targeted range, which valued the firm at £3.4bn at the start of trading.
Such a successful IPO is a shot in the arm for the UK economy at a time when ministers are looking to reform listing rules in order to attract healthy interest from the tech sector.
The Oxford-based company is likely to be one of the largest floats this year in London, with analysts valuing it at between £4 billion and £7 billion.
What does Oxford Nanopore do?
Unless you have an extensive knowledge of biochemistry, the Wikipedia entry for Oxford Nanopore Technologies may as well be written in Sanskrit.
“Oxford Nanopore Technologies Limited is a UK-based company which is developing and selling nanopore sequencing products (including the portable DNA sequencer, MinION) for the direct, electronic analysis of single molecules,” we are informed.
The company’s own website has some slightly more digestible information. The technology it develops provides “on-demand biological information, to any person, in any environment.”
Further reading suggests much of its work is used in research, in fields as diverse as forensics, space exploration, crop efficiency and food security. Its core operations are in cancer and infectious diseases.
And while Covid-19 has hardly spelt good news for the vast majority of the world's population, it has proved beneficial to a group of Oxford-based scientists.
How does Oxford Nanopore make money?
Oxford Nanopore's revenue comes from the funds it receives by other companies in the biotech sector who are keen to use its products for their own research and development purporses.
To that end, its impressive IPO should give it bigger reach in a sector that is notoriously competitive when it comes to business-to-business marketing.
What is Oxford Nanopore's business strategy?
Nanopore has laid out plans to tap into the growing genomic sequencing market, estimated to be worth $5.7bn globally.
At present, the company’s sequencing technology is mainly used by universities and labs conducting scientific research, but it sees great potential in areas such as infectious disease, immune profiling and cancer diagnostics, food safety and agriculture.
It has also provided rapid Covid-19 tests to the UK government, under contracts worth £144m. Its revenues more than doubled to £114m last year, and it is aiming to reduce its losses and break even in the next five years.
Is Oxford Nanopore profitable?
Oxford Nanopore has never made a profit and is still some way off breaking even, after reporting an operating loss of £73m in its 2020 financial year. Costs are likely to continue growing, believes Julian Roberts, of the investment banking group Jefferies, forecasting the business will not turn a profit until 2026.
That has not deterred initial investors, however. And Roberts told the Daily Telegraph its "scarcity value" - as one of the few biotech companies listing on London's stock market, rather than in the US - was a key attraction.
He added investors would value shares in Oxford Nanopore based on the growth potential of the business, rather than its current financial performance.
Biotech and life sciences have been earmarked by the conservative government of Boris Johnson as a sector the UK can dominate. To that end, officials are keen to facilitate processes that would allow a nucleus of such companies to develop in the UK.
What is the UK doing to facilitate tech IPOs?
The UK wants companies like Oxford Nanopore to remain with their feet firmly planted on home soil rather than be bought out by larger companies from overseas.
In February, ministers lent their support to a review into rules concerning London listings which can help keep tech companies in the UK. These measures include reforming the process to provide such greater scope for dual share classes, something that is in the interests of start-up founders.
How has the pandemic helped Oxford Nanopore grow?
The COVID-19 pandemic has proved to be a substantial economic benefit to Oxford Nanopore. Few organisations can provide such a powerful solution when it comes to spotting and tracking coronavirus mutations.
It’s been reported that approximately 20% of the Sars-Cov-2 virus genomes were generated on an Oxford Nanopore device by scientists from more than 85 countries.
Board of Directors of Oxford Nanopore
The Oxford Nanopore executive team has experience in the development, manufacture and commercialisation DNA sequencing. It is also committed to supporting future fundraising activities.
- Chief executive officer: Dr Gordon Sanghera
- Chief business development officer: Dr Spike Willcocks
- Chief technology officer: Clive Brown
- Chief scientific officer: Dr John Milton
- SVP, Corporate development: John Schoellerman
- Chief financial officer: Tim Cowper
- VP, Marketing: Zoe McDougall
- VP, General Counsel: Jordan Herman
How to trade stocks at FOREX.com
You can trade stocks with FOREX.com from some jurisdictions using spread-bets or CFDs, with spreads from 0.1%. Follow these easy steps to start trading now.
- Open a FOREX.com account or simply log-in if you’re already a customer.
- Search for the company you want to trade in our award-winning platform.
- Choose your position and size, and your stop and limit levels.
- Place the trade
Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.
Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.